Research Analysts Set Expectations for TRVI FY2030 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, May 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $0.70 for the year, down from their prior forecast of $0.79. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.46) per share.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Monday, April 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a report on Friday, April 17th. Morgan Stanley reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Trevi Therapeutics in a report on Wednesday. Needham & Company LLC reduced their target price on Trevi Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, JonesTrading reduced their target price on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $21.70.

Trevi Therapeutics Stock Down 2.7%

NASDAQ:TRVI opened at $14.26 on Thursday. The business’s 50-day simple moving average is $12.63 and its two-hundred day simple moving average is $11.92. The stock has a market cap of $1.83 billion, a PE ratio of -44.56 and a beta of 1.07. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRVI. AQR Capital Management LLC grew its position in Trevi Therapeutics by 20.4% in the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after acquiring an additional 4,688 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Trevi Therapeutics by 31.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after acquiring an additional 10,445 shares in the last quarter. Millennium Management LLC grew its position in Trevi Therapeutics by 356.3% in the first quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after acquiring an additional 642,830 shares in the last quarter. Strs Ohio purchased a new position in Trevi Therapeutics in the first quarter worth about $52,000. Finally, Creative Planning grew its position in Trevi Therapeutics by 17.5% in the second quarter. Creative Planning now owns 20,247 shares of the company’s stock worth $111,000 after acquiring an additional 3,016 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.